Get the Stockscreener App
18.96
1.94%
0.36
After Hours:
19.06
0.10
+0.53%
Ideaya Biosciences Inc stock is traded at $18.96, with a volume of 951.32K.
It is up +1.94% in the last 24 hours and down -8.67% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$18.60
Open:
$18.55
24h Volume:
951.32K
Relative Volume:
1.18
Market Cap:
$1.66B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-8.6575
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
-0.58%
1M Performance:
-8.67%
6M Performance:
-49.39%
1Y Performance:
-58.52%
1-Day Range:
$18.49
$19.59
1-Week Range:
$16.95
$19.67
52-Week Range:
$16.95
$46.40
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
18.96 | 1.66B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Ideaya Biosciences stock hits 52-week low at $17.28 By Investing.com - Investing.com Australia
Ideaya Biosciences stock hits 52-week low at $17.28 - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus.com
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up – What’s Next? - Defense World
IDEAYA Announces Further Gilead Sciences Clinical Study Collabor - GuruFocus.com
IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform - Insider Monkey
Top 10 AI Trending News on Wall Street - Insider Monkey
IDEAYA Biosciences Partners With ATTMOS To Advance AI/ML-Driven Oncology Drug Discovery - Nasdaq
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accele - GuruFocus.com
Ideaya Biosciences stock hits 52-week low at $19.95 - Investing.com India
Ideaya Biosciences stock hits 52-week low at $19.95 By Investing.com - Investing.com South Africa
IDEAYA Biosciences, ATTMOS Collaborate to Advance Small Molecule Discovery for Undruggable Oncology Targets - Marketscreener.com
Can AI Finally Crack "Undruggable" Cancer Targets? IDEAYA's New Tech Partnership Aims to Revolutionize Oncology - StockTitan
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire
Rhumbline Advisers Has $2.92 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Rule 5635(c)(4) - Nasdaq
IDEAYA Biosciences Grants Stock Options to 4 New Employees Under Inducement Plan - StockTitan
When the Price of (IDYA) Talks, People Listen - Stock Traders Daily
Fair Value analysis proves accurate as IDEAYA shares drop 41% in 10 months - Investing.com India
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month LowWhat's Next? - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results, Misses Expectations By $0.82 EPS - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month Low – Here’s Why - Defense World
IDEAYA Biosciences, Inc. SEC 10-K Report - TradingView
Fiera Capital Corp Has $30.44 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences' SWOT analysis: cancer therapy stock poised for pivotal year - Investing.com
How To Trade (IDYA) - Stock Traders Daily
IDEAYA announces proposed public offering of common stock and pre-funded warrants - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.8%Time to Sell? - MarketBeat
IDEAYA Biosciences Stock Gains Momentum as Analysts Reaffirm Bullish Outlook - HPBL
IDEAYA Biosciences' (IDYA) "Overweight" Rating Reiterated at Stephens - MarketBeat
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA) - MSN
IDEAYA Biosciences (IDYA) Expected to Announce Earnings on Tuesday - MarketBeat
IDEAYA Biosciences Reports 2024 Financials and Business Update - TipRanks
WCM Investment Management LLC Buys Shares of 241,894 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock hits 52-week low at $21.02 By Investing.com - Investing.com Australia
Q1 Earnings Estimate for IDYA Issued By Leerink Partnrs - MarketBeat
IDEAYA BIOSCIENCES Earnings Results: $IDYA Reports Quarterly Earnings - Nasdaq
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss - MSN
Ideaya Biosciences falls as quarterly loss widens - TradingView
IDEAYA Biosciences Launching Gilead Trial Collaboration to Evaluate Trodelvy, IDE397 Combination in Lung Cancer - Marketscreener.com
IDEAYA announces expanded collaboration with Gilead Sciences - MSN
Ideaya Biosciences enters additional supply pact with Gilead for IDE397 - TipRanks
Amgen ends Ideaya cancer combination trial after partner unveils rival molecule - Fierce Biotech
IDEAYA Biosciences Q4 Loss Widens, Revenue Rises -February 13, 2025 at 06:59 am EST - Marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences Posts Q4 Collaboration Revenue of $7M - Marketscreener.com
IDEAYA Q4 Earnings: Massive $1.1B War Chest Fuels Breakthrough Cancer Drug Development - StockTitan
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - Nasdaq
Ideaya Biosciences stock hits 52-week low at $21.02 - MSN
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):